Korsana Biosciences completed its merger with Cyclerion Therapeutics and raised $380 million in a private placement, boosting its cash to $456.2 million as of September 30, 2026. The company is advancing its lead Alzheimer’s drug candidate, KRSA-028, with Phase 1 healthy volunteer data expected by mid-2027 and interim patient data by late 2027 or early 2028. Korsana also strengthened its leadership team and plans to present preclinical data at the CTAD 2026 conference. The cash position is expected to fund operations through 2029, supporting ongoing research and development efforts.
Korsana Biosciences reported a strong cash position of $456.2 million as of September 30, 2026, following its merger and private placement. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health stocks, 94 rose and 48 fell. Notable movers include BKD at USD 10.69 with a 1-day change of -4.47%, TAK at USD 21.80 with a 1-day change of +3.51% and 100% sell order activity, and MESO at USD 14.79 with a 1-day change of +3.50%.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
